Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Protalix Announces Strategy for Novel CF Drug AIR DNase for Recurrent ...
BioPharma Investor: Gaucher Disease and FDA Fast Track for Protalix
Protalix BioTherapeutics, Inc. (PLX) Stock | Agreement with Pfizer Nets ...
Protalix Biotherapeutics KOL Breakfast: Protalix Presents following ...
About us | Protalix
Protalix BioTherapeutics - Israeli Startup | Startup Nation Finder
Protalix BioTherapeutics Outlines Strategic Roadmap for 2025 | NYSE:PLX
Protalix jumps after FDA approval - Globes
Protalix BioTherapeutics, Inc. (NYSE American: PLX): Virtual Investor ...
Protalix Enrolls First Gaucher Patient in Phase 2 Trial - Drug ...
PROTALIX BIOTHERAPEUTICS, INC._December 31, 2024
Q3 Track 1: Protalix BioTherapeutics, Inc. - Investor Summit Group
Protalix Biotherapeutics, Inc. (PLX) 8-K Earnings Release, Regulated ...
Protalix reaches agreement with FDA on Fabry data package, but ...
Protalix BioTherapeutics, Inc. (PLX) BCG Matrix Analysis – DCFmodeling.com
Protalix BioTherapeutics Stock: FDA Approval For Elfabrio To Drive ...
Elfabrio® | Protalix
Protalix Biotherapeutics Careers | Levels.fyi
Protalix and Chiesi Global Rare Diseases today announced that the U.S ...
Protalix Biotherapeutics Granted Fda Fast Track Designation ...
Protalix BioTherapeutics, Inc. Stock — PLX Overview — Roic AI
Protalix BioTherapeutics, Inc. (PLX): Company Profile – DCFmodeling.com
Protalix BioTherapeutics: A Hidden Gem in Biopharma, Poised for Takeoff ...
Protalix BioTherapeutics, Inc. (PLX) Stock Price, News, Quote & History ...
Protalix BioTherapeutics Unveils Strong Financial Growth and Ambitious ...
tulinercept (OPRX-106) / Protalix
PROTALIX BIOTHERAPEUTICS: Protalix BioTherapeutics and Chiesi Global ...
Protalix BioTherapeutics 2024 sonuçlarını açıkladı - Midas
Protalix BioTherapeutics logo in transparent PNG format
Protalix up 74% after positive Fabry disease trial results - Globes
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into ...
Protalix BioTherapeutics, Inc. (PLX) Stock Price, Quote, History & News ...
Protalix Biotherapeutics Inc. (PLX) Soars 2.70% on FDA Clearance ...
Protalix BioTherapeutics CEO outlines 2026 priorities, highlights ...
Will Protalix BioTherapeutics Keep Powering Higher After its 178% Run ...
Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the ...
Protalix Biotherapeutics poised for profitability as rare disease drug ...
Protalix Biotherapeutics is developing innovative treatments for rare ...
Careers | Protalix
Protalix Biotherapeutics Announces Feasibility Study with Kirin ...
Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well ...
Protalix BioTherapeutics, Inc. (PLX) ANSOFF Matrix Analysis ...
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2025 Earnings Call ...
Pioneering Protein Solutions | Protalix
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update ...
Protalix BioTherapeutics PLX 4Q and Yearly Summary 18Mar2024 - YouTube
Protalix BioTherapeutics: Debt-Free and Ready to Conquer 2025
Protalix Biotherapeutics
Protalix BioTherapeutics, Inc. Stock Report — PLX Analysis — Roic AI
Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics granted FDA Fast Track Designation for PRX-102 ...
Protalix BioTherapeutics, Inc. Financial Ratios — PLX Stock — Roic AI
Protalix BioTherapeutics CEO Outlines 2026 Strategic Roadmap for Rare ...
Pipeline | Protalix
Protalix BioTherapeutics, Inc. (PLX): Business Model Canvas ...
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2024 Earnings Call Transcript
Protalix BioTherapeutics Corporate Update January 2017
Protalix CEO Dror Bashan comments on the positive topline results from ...
Protalix Finalizes Accelerated Approval Pathway for PRX-102
Secarna Pharmaceuticals and Protalix Biotherapeutics Enter into ...
Protalix Biotherapeutics gains momentum in the rare disease space ...
[ 미국 주식] Protalix BioTherapeutics, Inc(PLX, 프로탈릭스 바이오테라퓨틱스) 주가가 급등한 이유는 ...
Gwen A. Melincoff - Director at Protalix BioTherapeutics | The Org
Protalix BioTherapeutics A Hold Pending Successful Commercialization Of ...
Protalix BioTherapeutics PLX 1Q 2025 Quarterly Summary 12May2025 - YouTube
Protalix BioTherapeutics Stock: Strong Buy With A Promising Pipeline ...
Protalix BioTherapeutics PLX Approval Summary 10May2023 - YouTube
Protalix – Fiocruz, Gaucher Disease Therapy Technology Transfer and ...
Protalix Biotherapeutics posted on LinkedIn
Protalix Resubmits To FDA The BLA For Pegunigalsidase Alfa For ...
Protalix BioTherapeutics (PLX) price target decreased by 10.71% to 12.75
PRX-119 | Protalix
Compre ações Protalix BioTherapeutics | Preço por ação $PLX | Lightyear
protalix biotherapeutics inc the offices of lifesci advisors 250 w 55th ...
PLX Stock Price and Chart — AMEX:PLX — TradingView
Protalix’ oral anti-TNF drug hits the mark in phase 2 ulcerative ...
首家通过FDA批准的利用植物悬浮细胞生产药用蛋白企业Protalix解析
Protalix, the first FDA-approved company to use plant suspension cells ...
Chiesi, Protalix’s PRX-102 secure FDA nod to treat Fabry disease
Top 100 Protein Engineering Companies in Israel (2026) | ensun
(PDF) Large scale production of pharmaceutical proteins in plant cell ...
Protalix, Pfizer enter clinical development deal
Chiesi’s Elfabrio (pegunigalsidase alfa) Receives NICE Recommendation ...
PLX: FDA Approval of Elfabrio
Graphic
Protalix, Secarna Pharmaceuticals enter collaboration and option agreement
About Us - Danyel Biotech
法布里病新药！Protalix/凯西长效α-半乳糖苷酶A产品pegunigalsidase alfa获美国FDA优先审查！ - FDA信息专区 ...
Prostalix Capsule - Herbax Ayurveda
Protalix, Chiesi Launch Expanded Access Program for PRX-102 in the US
